Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kadmon has announced the execution of a co-promotion agreement between its wholly-owned subsidiary, Kadmon Pharmaceuticals, and Valeant Pharmaceuticals North America in which Kadmon has been granted US rights to co-promote Syprine (trientine hydrochloride) capsules, a chelation therapy indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine.
Subscribe to our email newsletter
Kadmon will co-promote the product through its sales force and extensive network of specialty pharmacies. Financial terms of the agreement were not disclosed.
Kadmon chairman and CEO Samuel D Waksal noted this agreement adds an important new therapy to its growing commercial business, expanding its focus beyond the treatment of Hepatitis C.
"By utilizing our commercial platform to raise awareness of Wilson’s disease through increased education, promotion and distribution of SYPRINE, we believe we can better serve patients with this rare genetic disorder.
"This is an important step in expanding the scope of our commercial reach, which we will continue to grow through further commercial agreements as we develop our pipeline of product candidates. We are focused on developing drugs that have a profound impact on diseases for which there are no alternative therapies, predominantly in the areas of oncology, inflammatory disorders and rare genetic diseases," Waksal added.